Hepatitis C Treatment Snapshots: Daclatasvir

Hepatitis C Treatment Snapshots: Daclatasvir

For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.

/ News

Share the Post

Related Posts

Factsheet on updated WHO guidelines for the screening, care and treatment of persons with hepatitis C infection from TREAT Asia/amfAR
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Part 1: What is hepatitis C and how is it diagnosed?
Letter from Asian community and treatment advocates to Chief Executive Officer of CHAI regarding the Quick start program and concerns that patients would have to pay for sofosbuvir and diagnostics to be a part of the program in October 2016
Support letter for inclusion of Daclatasvir on 4th March, 2015.
The Updated Pricing of Ledipasvir and Sofosbuvir Co-formulated tablets